ArticleSpringerPlus2014

Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL.

Karin Hohloch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.